Get the Stockscreener App
0.0222
2.14%
0.000464
After Hours:
.02
-0.00216
-9.76%
Geovax Labs Inc stock is traded at $0.0222, with a volume of 3,669.
It is up +2.14% in the last 24 hours and down -61.65% over the past month.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
See More
Previous Close:
$0.0217
Open:
$0.022
24h Volume:
3,669
Relative Volume:
0.22
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-32.63%
1M Performance:
-61.65%
6M Performance:
-78.27%
1Y Performance:
-35.76%
1-Day Range:
$0.022
$0.0251
1-Week Range:
$0.0217
$0.0354
52-Week Range:
$0.0217
$34.93
Geovax Labs Inc Stock (GOVXW) Company Profile
Name
Geovax Labs Inc
Sector
Industry
Phone
678 384 7220
Address
1900 Lake Park Drive, Suite 380, Smyrna
Compare GOVXW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOVXW
Geovax Labs Inc
|
0.0222 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Geovax Labs Inc Stock (GOVXW) Latest News
D. Boral Capital Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $9.00 - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Geode Capital Management LLC Has $223,000 Holdings in GeoVax Labs, Inc. (NASDAQ:GOVX) - Defense World
Geovax highlights progress on mpox vaccine and COVID-19 trial advancements - MSN
GeoVax Labs Earnings Call: Mixed Sentiment and Future Prospects - TipRanks
Geovax Labs (GOVX) Faces Price Target Reduction by Analyst | GOV - GuruFocus
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
GeoVax Labs Reports Q1 2025 Progress Amid Challenges - TipRanks
Earnings call transcript: GeoVax Q1 2025 reveals revenue from BARDA contract - Investing.com
GeoVax Labs Q1 2025 Earnings Call Transcript - MarketBeat
Geovax Labs is a buy, Roth says - Cantech Letter
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - ADVFN
GOVX’s 2023 Market Dance: Down -59.51% – Time to Invest? - investchronicle.com
Geovax Labs Inc (GOVX) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater - Yahoo Finance
GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress - Yahoo Finance
GeoVax to Host Q1 2025 Financial Results Conference Call, Spotlight COVID-19 Vaccine and Cancer Therapy Progress - citybuzz -
GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025 - The Globe and Mail
GeoVax Bolsters Technical Development with Seasoned Biologics Executive - citybuzz -
GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations - The Globe and Mail
Analysts Issue Forecasts for GeoVax Labs FY2029 Earnings - Defense World
HC Wainwright Estimates GeoVax Labs FY2025 Earnings - Defense World
Alliance Global Partners Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $8.50 - Defense World
HC Wainwright Reiterates Buy Rating for GeoVax Labs (NASDAQ:GOVX) - Defense World
Q2 EPS Estimates for GeoVax Labs Lowered by Noble Financial - Defense World
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates - Yahoo Finance
GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital - Yahoo Finance
GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum - Yahoo Finance
Geovax Labs stock hits 52-week low at $0.78 amid market challenges By Investing.com - Investing.com South Africa
Top Midday Decliners - marketscreener.com
These Numbers Reveal How Powerful Geovax Labs Inc (NASDAQ: GOVX) Stock Is - stocksregister.com
GeoVax Labs (GOVX) Faces Setback with Price Target Reduced by Ro - GuruFocus
GeoVax Labs (GOVX) Faces Setback with Price Target Reduced by Roth Capital | GOVX Stock News - GuruFocus
GeoVax to Present at the Emerging Growth Conference on April 16, 2025 - Yahoo Finance
GeoVax (GOVX) Faces Setback with Termination of COVID-19 Vaccine Project | GOVX Stock News - GuruFocus
GeoVax's COVID-19 Vaccine Study Ended by Funding Agency; Shares Fall - MarketScreener
GeoVax Labs (GOVX) Faces Setback as BARDA-Funded Trial Ends | GO - GuruFocus
Geovax Labs stock hits 52-week low at $0.78 amid market challenges - Investing.com Canada
GeoVax to Present Clinical Data at Upcoming April Industry Events - Yahoo Finance
GeoVax Labs (GOVX): Price Target Lowered Amid BARDA Project Pause | GOVX Stock News - GuruFocus
GeoVax Labs contract with BARDA terminated By Investing.com - Investing.com South Africa
GeoVax Labs Got Written Notification From Advanced Technology International - MarketScreener
GeoVax tumbles as HHS ends mid-stage COVID vaccine trial - TradingView
GeoVax Labs contract with BARDA terminated - Investing.com
Geovax labs director John Spencer buys $9,800 in stock - Investing.com Australia
GeoVax Labs (NASDAQ:GOVX) Earns “Buy” Rating from D. Boral Capital - Defense World
Geovax labs director John Spencer buys $9,800 in stock By Investing.com - Investing.com Canada
Geovax labs VP John Sharkey acquires $5,940 in common stock By Investing.com - Investing.com Canada
GeoVax Labs (GOVX) Gains Favor with BARDA Contract Amid FDA Vacc - GuruFocus
Geovax labs VP John Sharkey acquires $5,940 in common stock - Investing.com Australia
GeoVax Labs, Inc. (NASDAQ:GOVX) Given Average Recommendation of “Buy” by Analysts - Defense World
Geovax Labs Inc Stock (GOVXW) Financials Data
There is no financial data for Geovax Labs Inc (GOVXW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Cap:
|
Volume (24h):